Warning letter
Hawkeye Jensen Inc [ARCHIVED]: warning letter of Feb 8, 2011
FDA warning letter 138451 · Philadelphia District Office
Key facts
| Reference number | 138451 |
|---|---|
| Company | Hawkeye Jensen Inc [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Misbranded/Adulterated |
| Issue date | Feb 8, 2011 |
| Posted date | Feb 8, 2011 |
| Issuing office | Philadelphia District Office |
| Product type | Drugs |
| CFR sections cited | 201.66(b)(2), 347, 211.22(d), 211.25(c), 211.100(a), 211.165(a), 310.545(a)(18), 347.20(d), 211.67(b), 201.115, 201.10(c)(1) |
| Inspection city | Shartlesville |
| Inspection ZIP | 19554 |
| Inspection start date | Aug 4, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: